Oral Melanoma

Oral melanoma is a malignant neoplasm arising from melanocytes within the oral cavity, representing the most common oral malignancy in dogs and a rare but aggressive tumor in cats. It is characterized by local invasiveness, high metastatic potential, and a poor prognosis. The tumor can arise from the gingiva, buccal mucosa, palate, lips, or tongue, with a predilection for the gingival and labial mucosa. Histologically, melanomas exhibit a range of morphologies, from epithelioid to spindle cell types, and may be amelanotic, making diagnosis challenging. The biological behavior is aggressive, with early regional lymph node metastasis and distant spread to lungs, liver, and other organs. Staging is critical for prognosis and treatment planning, with the World Health Organization (WHO) staging system commonly used. Oral melanoma is distinct from cutaneous melanoma in its more aggressive course and poorer response to conventional therapies. In dogs, it accounts for 30-40% of all oral tumors, while in cats it is rare but highly malignant. The tumor is locally destructive, causing bone lysis, tooth loss, and functional impairment. Early detection and aggressive multimodal therapy are essential for improving outcomes, though the overall prognosis remains guarded to poor.

The exact etiology of oral melanoma is not fully understood, but it is believed to arise from malignant transformation of melanocytes, which are derived from neural crest cells. Several factors have been implicated in the pathogenesis: genetic mutations, such as in the BRAF gene (though less common in dogs than in humans), NRAS mutations, and alterations in tumor suppressor genes like p53 and PTEN. Ultraviolet (UV) radiation is a well-known risk factor for cutaneous melanoma in humans, but its role in oral melanoma is less clear, as the oral cavity is shielded from UV exposure. However, chronic inflammation, trauma, and exposure to environmental carcinogens (e.g., tobacco smoke, certain chemicals) may contribute. In dogs, a genetic predisposition is suggested by the higher incidence in breeds with pigmented oral mucosa, such as Chow Chows, Golden Retrievers, and Poodles, though no specific genetic marker has been identified. Viral etiologies have been proposed but not confirmed. Immunosuppression, either from concurrent disease or iatrogenic causes, may also play a role in tumor development. The molecular pathways involved include activation of the MAPK/ERK pathway, PI3K/AKT signaling, and dysregulation of apoptosis. Further research is needed to elucidate the precise molecular triggers.

Oral melanoma predominantly affects dogs, with a higher incidence in older animals (median age 10-12 years). There is no strong sex predilection, though some studies suggest a slight male predominance. Breeds with increased risk include Chow Chows, Golden Retrievers, Poodles, Cocker Spaniels, and dogs with heavily pigmented oral mucosa. The tumor is rare in cats, but when it occurs, it is typically in older cats (median age 12-14 years) and is highly malignant. Geographic variation is not well-documented, but the disease is seen worldwide. In dogs, oral melanoma accounts for approximately 30-40% of all oral tumors, making it the most common oral malignancy. The annual incidence is estimated at 1-2 per 10,000 dogs. There is no seasonal variation. The aggressive nature of the tumor is reflected in the high metastatic rate at diagnosis: approximately 30-40% of dogs have regional lymph node metastasis at presentation, and up to 80% will develop distant metastasis within 1 year if untreated. Breed-specific genetic risk factors are suspected, but no definitive genetic markers have been identified. The disease is more common in dogs with dark oral pigmentation, suggesting a role for melanocyte density.

Oral melanoma arises from melanocytes in the oral mucosa, which undergo malignant transformation due to genetic and environmental factors. The tumor cells exhibit uncontrolled proliferation, local invasion, and metastasis. At the cellular level, mutations in oncogenes (e.g., BRAF, NRAS) and tumor suppressor genes (e.g., p53, PTEN) lead to dysregulation of cell cycle, apoptosis, and cell adhesion. The tumor microenvironment, including inflammatory cells, fibroblasts, and angiogenic factors, promotes tumor growth and invasion. The neoplastic cells produce melanin, which can be pigmented or amelanotic. Local invasion is facilitated by matrix metalloproteinases (MMPs) that degrade extracellular matrix, allowing tumor infiltration into underlying bone and soft tissues. The rich vascular and lymphatic supply of the oral cavity facilitates early metastasis. Hematogenous spread to the lungs, liver, and other organs occurs via the bloodstream, while lymphatic spread to regional lymph nodes (mandibular, retropharyngeal) is common. The tumor induces angiogenesis through vascular endothelial growth factor (VEGF) secretion, supporting its growth and metastatic potential. Systemic effects include paraneoplastic syndromes, such as hypercalcemia, though rare. The aggressive clinical course is due to the high proliferative index and resistance to apoptosis. Understanding these mechanisms is crucial for developing targeted therapies.

Predisposing factors for oral melanoma include intrinsic and extrinsic elements. Intrinsic factors: (1) Genetic predisposition: certain breeds (Chow Chow, Golden Retriever, Poodle) have a higher risk, possibly due to inherited mutations in genes like BRAF or p53. (2) Age: older animals (median 10-12 years in dogs) are more susceptible due to accumulated genetic damage. (3) Pigmentation: animals with heavily pigmented oral mucosa have a higher risk, as melanocytes are the cells of origin. (4) Immunosuppression: concurrent diseases (e.g., ehrlichiosis, leishmaniasis) or immunosuppressive therapy may impair immune surveillance. Extrinsic factors: (1) Environmental carcinogens: exposure to tobacco smoke, certain chemicals, or chronic irritation from poor dental hygiene may contribute. (2) Trauma: chronic mechanical irritation from sharp teeth or foreign bodies may promote malignant transformation. (3) UV radiation: though less relevant for oral cavity, it may play a role in lip melanomas. (4) Diet: no specific dietary factors are identified. (5) Concurrent infections: chronic periodontitis or viral infections (e.g., papillomavirus) may act as cofactors. Management practices, such as lack of routine oral examinations, may delay detection, allowing progression.

Clinical signs of oral melanoma vary with tumor location, size, and stage. Early signs may be subtle and include: (1) Oral mass: a visible, often pigmented (black/brown) or amelanotic (pink/white) mass on the gingiva, lips, palate, or tongue. (2) Halitosis: due to tumor necrosis and secondary infection. (3) Ptyalism (excessive drooling). (4) Dysphagia: difficulty eating, especially if the tumor involves the tongue or pharynx. (5) Oral bleeding: from ulceration or trauma. (6) Loose teeth: due to bone invasion. (7) Facial swelling: if the tumor invades underlying bone or soft tissues. (8) Pain: evidenced by pawing at the mouth, reluctance to eat, or aggression when the mouth is touched. As the disease progresses, systemic signs may appear: (1) Weight loss and anorexia. (2) Lethargy. (3) Respiratory distress if metastasis to the lungs occurs. (4) Lymphadenopathy: enlargement of mandibular or retropharyngeal lymph nodes due to metastasis. (5) Neurologic signs if brain metastasis occurs (rare). In advanced stages, the tumor may become ulcerated, infected, and malodorous. The clinical stage at presentation is a major determinant of prognosis.

Differential diagnoses for oral melanoma include: (1) Oral squamous cell carcinoma: more common in cats, often non-pigmented, arises from gingiva or tongue, locally invasive but less metastatic. Histopathology and immunohistochemistry (IHC) for melanocytic markers (Melan-A, PNL2, S100) differentiate. (2) Oral fibrosarcoma: firm, non-pigmented mass, often on gingiva, locally aggressive, low metastatic potential. Biopsy shows spindle cells with collagen production. (3) Oral osteosarcoma: rare, arises from bone, may be pigmented if melanin is present, but histopathology shows osteoid production. (4) Epulides (peripheral odontogenic fibroma, acanthomatous ameloblastoma): benign, slow-growing, often non-pigmented, arise from periodontal ligament, do not metastasize. Histopathology is diagnostic. (5) Oral papillomatosis: viral-induced, cauliflower-like, multiple, usually in young dogs, regress spontaneously. (6) Granulomatous inflammation (e.g., fungal, foreign body): may present as a mass, but biopsy shows inflammatory infiltrate. (7) Amelanotic melanoma: must be distinguished from other non-pigmented tumors; IHC is essential. (8) Metastatic tumors to the oral cavity: rare, but primary tumors elsewhere (e.g., mammary, lung) may metastasize. Key distinguishing features: pigmentation, location, growth rate, and histopathology with IHC.

The diagnostic algorithm for oral melanoma follows a stepwise approach: (1) Complete history and physical examination, including thorough oral examination under sedation or anesthesia to assess the mass, palpate regional lymph nodes, and evaluate for bone involvement. (2) Fine-needle aspiration (FNA) of the mass and any enlarged lymph nodes for cytology. Cytology may show melanin-laden cells, but amelanotic tumors require IHC. (3) Biopsy (incisional or excisional) for histopathology. Biopsy is the gold standard for diagnosis and grading. (4) Immunohistochemistry (IHC) for melanocytic markers (Melan-A, PNL2, S100, tyrosinase) to confirm melanocytic origin, especially for amelanotic tumors. (5) Staging: (a) Thoracic radiographs (three views) to detect pulmonary metastasis. (b) Abdominal ultrasound to evaluate for liver, spleen, or other abdominal metastasis. (c) Computed tomography (CT) of the head and neck to assess local tumor extent, bone invasion, and lymph node involvement. CT is superior to radiography for evaluating the oral cavity and mandibular lymph nodes. (d) Lymph node evaluation: FNA or biopsy of mandibular and retropharyngeal lymph nodes, even if not enlarged, as micrometastasis is common. (6) Advanced imaging: MRI may be used for detailed soft tissue assessment, but CT is usually sufficient. (7) Baseline bloodwork (CBC, biochemistry, urinalysis) to assess overall health and identify paraneoplastic syndromes. (8) Genetic testing: not routinely performed but may be used for prognostic information (e.g., BRAF mutation status). The diagnostic algorithm should be completed within 1-2 weeks to allow timely treatment planning.

Laboratory findings in oral melanoma are often non-specific but may reflect systemic effects or concurrent disease. Hematology: (1) Complete blood count (CBC) may be normal, but anemia of chronic disease (normocytic, normochromic) may be present. (2) Leukocytosis may occur due to secondary infection or inflammation. (3) Thrombocytopenia is rare but may occur with bone marrow metastasis. Serum biochemistry: (1) Hypercalcemia may occur as a paraneoplastic syndrome, though rare. (2) Liver enzyme elevations (ALP, ALT) may indicate hepatic metastasis. (3) Azotemia (elevated BUN, creatinine) may be due to renal metastasis or dehydration. (4) Hypoalbuminemia may occur with chronic inflammation or protein-losing enteropathy. Urinalysis: (1) Usually normal, but proteinuria may be present with renal involvement. (2) Specific gravity may be low if hypercalcemia causes renal concentrating defects. Blood gas analysis: (1) May show metabolic acidosis if renal dysfunction is present. Specific biomarkers: (1) Serum thymidine kinase (TK) levels may be elevated in some malignancies, but not specific. (2) C-reactive protein (CRP) may be elevated as an inflammatory marker. (3) Melanoma-specific markers, such as circulating tumor DNA (ctDNA) or tyrosinase mRNA, are under investigation but not routinely available. Serology/PCR: (1) Not typically indicated unless infectious causes are suspected. (2) PCR for BRAF mutations may be performed on tumor tissue for prognostic purposes. Endocrine assays: (1) Not routinely needed unless hypercalcemia is present, then parathyroid hormone-related peptide (PTHrP) may be measured.

Imaging plays a crucial role in staging and treatment planning for oral melanoma. Radiography: (1) Thoracic radiographs (three views: right lateral, left lateral, ventrodorsal) are essential to detect pulmonary metastasis. Findings may include multiple nodular interstitial or alveolar patterns, often in the caudal lung lobes. (2) Dental radiographs of the affected area may show bone lysis, tooth root resorption, or periosteal reaction, but are limited in assessing soft tissue extent. Ultrasonography: (1) Abdominal ultrasound is used to evaluate for metastasis to the liver, spleen, kidneys, and lymph nodes. Findings may include hypoechoic nodules in the liver or spleen, or lymphadenopathy. (2) Ultrasound-guided FNA of abdominal organs can confirm metastasis. Computed Tomography (CT): (1) CT of the head and neck is the preferred imaging modality for local tumor staging. It provides detailed assessment of tumor size, extent, bone invasion (lytic or proliferative changes), and involvement of adjacent structures (e.g., mandible, maxilla, orbit). (2) CT can also evaluate regional lymph nodes (mandibular, retropharyngeal) for size, shape, and contrast enhancement, though normal-sized nodes may still contain micrometastasis. (3) CT of the thorax is more sensitive than radiography for detecting small pulmonary nodules. Magnetic Resonance Imaging (MRI): (1) MRI provides superior soft tissue contrast and is useful for assessing tumor invasion into the tongue, palate, or pharynx, and for evaluating perineural spread. (2) It is not routinely used due to cost and availability, but may be indicated for complex cases. Endoscopy: (1) Not typically used for oral melanoma, but may be used to evaluate the caudal oral cavity or pharynx. Fluoroscopy: (1) Not commonly used. Echocardiography: (1) Not indicated unless cardiac metastasis is suspected, which is rare.

Cytology and histopathology are essential for diagnosis and prognosis. Cytology (FNA): (1) FNA of the oral mass may yield cells with variable morphology. Pigmented melanomas show melanin granules (brown-black) in the cytoplasm, often obscuring the nucleus. Amelanotic melanomas may show epithelioid or spindle cells with prominent nucleoli, but are difficult to distinguish from other sarcomas or carcinomas. (2) FNA of regional lymph nodes can detect metastasis; the presence of melanin-laden cells is diagnostic. (3) Limitations: FNA may not provide enough tissue for grading, and false negatives can occur. Histopathology (biopsy): (1) Incisional or excisional biopsy is the gold standard. (2) Histologic features: neoplastic melanocytes arranged in nests, sheets, or fascicles. Cell types include epithelioid, spindle, or mixed. Melanin pigment may be present or absent (amelanotic). Nuclear atypia, high mitotic index (often >3 mitoses per 10 high-power fields), and areas of necrosis are common. (3) Grading: The Patnaik grading system (I, II, III) is based on mitotic index, nuclear pleomorphism, and tumor necrosis. Grade III tumors have a worse prognosis. (4) Immunohistochemistry (IHC): Positive staining for Melan-A, PNL2, S100, and tyrosinase confirms melanocytic origin. Ki-67 proliferation index may be used as a prognostic indicator. (5) Special stains: Fontana-Masson stain can highlight melanin, but IHC is more specific. (6) Sentinel lymph node biopsy: May be performed to detect micrometastasis, but is not routinely available.

Treatment of oral melanoma requires a multimodal approach. The primary treatment is surgical excision with wide margins (1-2 cm) and histologically clean margins. However, due to the anatomical constraints of the oral cavity, complete excision is often difficult. Surgical options include: (1) Mandibulectomy or maxillectomy for tumors involving the mandible or maxilla. (2) Glossectomy for tongue tumors. (3) Laser surgery or cryosurgery for small lesions. (4) Debulking surgery may be palliative. Radiation therapy is highly effective for local control, especially for incompletely excised tumors or as a primary treatment for non-resectable masses. Protocols: (1) Definitive radiation: 15-18 fractions of 3-4 Gy, total dose 48-57 Gy. (2) Hypofractionated: 4-6 fractions of 6-9 Gy, total dose 24-36 Gy. Radiation is often combined with surgery. Chemotherapy has limited efficacy, but may be used for metastatic disease. Drugs: (1) Carboplatin: 300 mg/m² IV every 3 weeks. (2) Cisplatin: 70 mg/m² IV every 3 weeks (requires saline diuresis). (3) Doxorubicin: 30 mg/m² IV every 3 weeks. Response rates are low (10-20%). Immunotherapy: (1) Canine melanoma vaccine (Oncept) is a xenogeneic DNA vaccine targeting tyrosinase. It is given as a series of 4 doses every 2 weeks, then every 6 months. It may prolong survival in dogs with stage II-III disease. (2) Checkpoint inhibitors (e.g., anti-PD-1/PD-L1) are under investigation. Targeted therapy: (1) Tyrosine kinase inhibitors (e.g., toceranib) may have activity in some tumors. Supportive care: (1) Pain management: NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h), opioids (e.g., tramadol 2-5 mg/kg PO q8-12h). (2) Nutritional support: feeding tubes if dysphagia. (3) Antibiotics for secondary infections. (4) Dental care. Emergency stabilization: (1) If the tumor causes airway obstruction, tracheostomy may be needed. (2) Fluid therapy for dehydration. The treatment plan should be tailored to the stage and grade of the tumor.

The prognosis for oral melanoma is generally poor to guarded. Median survival times (MST) vary with treatment: (1) Surgery alone: MST 5-9 months. (2) Surgery plus radiation: MST 10-18 months. (3) Radiation alone: MST 6-12 months. (4) Surgery plus vaccine: MST 12-18 months. Negative prognostic factors include: (1) Advanced stage (WHO stage III or IV). (2) Tumor size >2 cm. (3) High mitotic index (>3 per 10 HPF). (4) Presence of metastasis at diagnosis. (5) Incomplete surgical margins. (6) Amelanotic histology (often associated with higher grade). (7) Recurrence after treatment. Positive prognostic factors: (1) Early stage (I or II). (2) Complete surgical excision. (3) Low mitotic index. (4) Response to radiation therapy. The 1-year survival rate for dogs with stage I disease is approximately 50-60%, but drops to <10% for stage IV. Cats with oral melanoma have a very poor prognosis, with MST of 3-6 months despite treatment. Regular monitoring is essential to detect recurrence or metastasis early.

Follow-up for oral melanoma is intensive due to the high risk of recurrence and metastasis. Recommended schedule: (1) Recheck examinations every 1-3 months for the first year, then every 3-6 months thereafter. (2) Thoracic radiographs (3 views) every 3 months for the first year, then every 6 months. (3) Abdominal ultrasound every 6 months to check for abdominal metastasis. (4) Oral examination under sedation every 3-6 months to assess for local recurrence. (5) Lymph node palpation and FNA if enlarged. (6) Serial bloodwork (CBC, biochemistry) every 3-6 months to monitor for paraneoplastic syndromes or treatment-related toxicity. (7) If the patient received radiation therapy, monitor for radiation side effects (e.g., mucositis, osteonecrosis). (8) If the patient received the melanoma vaccine, booster doses are given every 6 months. (9) Quality of life assessments should be performed at each visit. (10) Owners should be educated on signs of recurrence (e.g., new mass, bleeding, difficulty eating) and metastasis (e.g., coughing, lethargy, weight loss). Early detection of recurrence may allow salvage therapy.

Pearls: (1) Always biopsy any oral mass, even if small, as early-stage oral melanoma can be cured with wide excision. (2) Use IHC (Melan-A, PNL2) for amelanotic tumors to avoid misdiagnosis. (3) Stage all patients with thoracic radiographs and lymph node evaluation, as micrometastasis is common. (4) Consider CT for surgical planning to assess bone invasion. (5) Combine surgery with radiation for best local control. (6) The melanoma vaccine may improve survival in dogs with stage II-III disease. (7) Manage pain aggressively to improve quality of life. Pitfalls: (1) Assuming a pigmented oral mass is benign; always biopsy. (2) Underestimating the metastatic potential; even small tumors can metastasize. (3) Incomplete staging leading to missed metastasis. (4) Relying solely on cytology for diagnosis; histopathology is essential. (5) Delaying treatment due to fear of surgery; early aggressive therapy improves outcomes. (6) Not considering radiation therapy for non-resectable tumors. (7) Overlooking the need for dental prophylaxis to prevent secondary infections.

Based on Plumb's Veterinary Drug Handbook, the following protocols are used for oral melanoma: (1) Chemotherapy: (a) Carboplatin: 300 mg/m² IV every 3 weeks for 4-6 cycles. Dose adjustment for renal impairment (reduce by 25% if creatinine >1.5 mg/dL). (b) Cisplatin: 70 mg/m² IV every 3 weeks, with saline diuresis (0.9% NaCl at 10-20 mL/kg/h for 4 hours before and after). Contraindicated in cats. (c) Doxorubicin: 30 mg/m² IV every 3 weeks, with cardiac monitoring. (2) Immunotherapy: (a) Canine melanoma vaccine (Oncept): 1 mL intradermal or subcutaneous every 2 weeks for 4 doses, then every 6 months. (3) Targeted therapy: (a) Toceranib (Palladia): 2.75-3.25 mg/kg PO every other day. Monitor for gastrointestinal and hematologic toxicity. (4) Analgesics: (a) Carprofen: 2.2 mg/kg PO q12h, or 4.4 mg/kg PO q24h. (b) Meloxicam: 0.1 mg/kg PO q24h. (c) Tramadol: 2-5 mg/kg PO q8-12h. (d) Gabapentin: 5-10 mg/kg PO q8-12h for neuropathic pain. (5) Antibiotics: (a) Amoxicillin-clavulanate: 13.75 mg/kg PO q12h for secondary infections. (b) Clindamycin: 5-10 mg/kg PO q12h for bone infections. (6) Gastroprotectants: (a) Omeprazole: 0.5-1 mg/kg PO q24h if NSAIDs are used. (7) Antiemetics: (a) Maropitant: 1 mg/kg SC or PO q24h for chemotherapy-induced nausea. (8) Supportive care: (a) Fluid therapy: isotonic crystalloids at maintenance (60-100 mL/kg/day) for dehydration. (b) Nutritional support: feeding tube if anorexic. All protocols should be adjusted based on renal/hepatic function and monitored for adverse effects.

Key literature on oral melanoma includes: (1) Bergman et al. (2006) reported that the xenogeneic DNA vaccine (Oncept) significantly prolonged survival in dogs with stage II-III oral melanoma, with a median survival of 389 days compared to historical controls. (2) Proulx et al. (2003) demonstrated that radiation therapy (hypofractionated) provided local control in 80% of dogs with oral melanoma, with a median progression-free interval of 8 months. (3) The Veterinary Society of Surgical Oncology (VSSO) consensus guidelines recommend surgical excision with 1-2 cm margins as the primary treatment, with adjuvant radiation for incomplete margins. (4) A study by Boston et al. (2014) found that mitotic index is a strong prognostic indicator, with tumors having >3 mitoses per 10 HPF associated with a 2-fold increased risk of metastasis. (5) The ACVIM consensus statement on cancer staging (2016) emphasizes the importance of lymph node evaluation, including sentinel lymph node biopsy, for accurate staging. (6) A meta-analysis by Smedley et al. (2011) reported that the overall metastatic rate for oral melanoma is 30-40% at diagnosis, increasing to 80% at 1 year. (7) Recent studies on checkpoint inhibitors (e.g., anti-PD-1) in canine melanoma have shown promising results, with response rates of 20-30% in clinical trials. (8) The World Health Organization (WHO) staging system for oral melanoma is widely used and has been validated in multiple studies. (9) A study by Gardner et al. (2015) found that CT is superior to radiography for detecting pulmonary metastasis, with a sensitivity of 90% vs. 60%. (10) The use of toceranib in oral melanoma has been evaluated in a phase I trial, showing a disease control rate of 50% in a small cohort. These studies support the current multimodal approach and highlight the need for early detection and aggressive therapy.